One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Journals package 3months
-
http://medilib.ir
- Duration of Time : 93 Day
- :
Price : 100$- Special Price : 50$
Table of Contents
doi : 10.1016/S0923-7534(25)00884-1
Volume 36, Issue 9, September 2025, Pages i-ii
Long-term development after maternal cancer treatment: some reassurance but still open questions
Localised rectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆
Long-term development of 12- and 15-year-old offspring after maternal cancer diagnosis during pregnancy: a prospective multicentre cohort study
Twenty-year survival of advanced gastrointestinal stromal tumours treated with imatinib: exploratory long-term follow-up of the BFR14 trial
Ultrasensitive detection and tracking of circulating tumor DNA to predict relapse and survival in patients with locally advanced cervical cancer: phase III CALLA trial analyses
Enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer: results of the EORTC 1333/PEACE-3 trial
Association of the circulating lipid panel, PCPro, with clinical outcomes in metastatic hormone-sensitive prostate cancer: post hoc analysis of the ENZAMET phase III randomised trial (ANZUP 1304)
Copenhagen Prospective Personalized Oncology (CoPPO)—impact of comprehensive genomic profiling in more than 2000 patients in a phase I setting
Avelumab plus sacituzumab govitecan versus avelumab monotherapy as first-line maintenance treatment in patients with advanced urothelial carcinoma: JAVELIN Bladder Medley interim analysis☆
Spatiotemporal T-cell tracking for personalized T-cell receptor T-cell therapy designs in childhood cancer
Letter to the editor ‘A pooled analysis of trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer with brain metastases’ by F. André et al.
Reply to Letter to the Editor: ‘A pooled analysis of trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer with brain metastases’ by Y. Liu & C. Zhang
